Eva Lin
Impact in
- Neurology top 1%
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
-
- Nerve injury and regeneration
- Nuclear Receptors and Signaling
Papers in
-
- Melanoma and MAPK Pathways 7
- PI3K/AKT/mTOR signaling in cancer 3
-
- Cancer Genomics and Diagnostics 5
- Co-authors
- Ruth G. Perez (4 shared papers)Michael J. Zigmond (4 shared papers)Jack C. Waymire (2 shared papers)Fengli Guo (2 shared papers)Jeff Settleman (6 shared papers)Richard M. Neve (5 shared papers)Hartmut Koeppen (2 shared papers)John G. Moffat (2 shared papers)
- Journals
- Clinical Cancer Research (3 papers)Cancer Research (3 papers)Nature (2 papers)Molecular Cancer Research (2 papers)Cancer Discovery (1 paper)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Eva Lin
27 papers receiving 3.3k citations
Eva Lin's Hit Papers
Peers
Comparison fields: 5 of 117
- Neurology 932
- Cellular and Molecular Neuroscience 671
- Oncology 975
- Cancer Research 377
- Molecular Biology 1.5k
Countries citing papers authored by Eva Lin
This map shows the geographic impact of Eva Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Lin more than expected).
Fields of papers citing papers by Eva Lin
This network shows the impact of papers produced by Eva Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Lin. The network helps show where Eva Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Hit paper breakdown → | 2012 | 884 |
| 2 | A role for alpha-synuclein in the regulation of dopamine biosynthesis. Hit paper breakdown → | 2002 | 535 |
| 3 | A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis Hit paper breakdown → | 2002 | 501 |
| 4 | 2009 | 231 | |
| 5 | 2008 | 198 | |
| 6 | 2016 | 185 | |
| 7 | 2014 | 116 | |
| 8 | 2014 | 110 | |
| 9 | 2004 | 95 | |
| 10 | 2003 | 72 | |
| 11 | 2007 | 54 | |
| 12 | 2009 | 51 | |
| 13 | 2001 | 49 | |
| 14 | 2018 | 47 | |
| 15 | 2018 | 47 | |
| 16 | 2023 | 38 | |
| 17 | 2020 | 37 | |
| 18 | 2019 | 37 | |
| 19 | 2003 | 22 | |
| 20 | 2021 | 20 |
About Eva Lin
Eva Lin is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Cell Biology, having authored 29 papers that have together received 3.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (7 papers), Cancer Genomics and Diagnostics (5 papers), Hippo pathway signaling and YAP/TAZ (3 papers), Lung Cancer Treatments and Mutations (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Phagocytosis and Immune Regulation (2 papers), Computational Drug Discovery Methods (2 papers) and Nerve injury and regeneration (2 papers). The work is most often cited by research in Neurology (932 citations), Cellular and Molecular Neuroscience (671 citations), Oncology (975 citations), Cancer Research (377 citations) and Molecular Biology (1.5k citations). Eva Lin has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Ruth G. Perez, Michael J. Zigmond, Jack C. Waymire, Fengli Guo, Jeff Settleman, Richard M. Neve, Hartmut Koeppen, John G. Moffat, Mark Merchant and Yibing Yan. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Nature, Molecular Cancer Research and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.